17.3.2020

Capitalising on Fear Prohibited in Marketing

The outbreak of COVID-19, or the coronavirus, has been declared a pandemic, and its impacts are being felt in every corner of society. Unfortunately, this public health emergency is being taken advantage of in the form of questionable product marketing.

In response to improper marketing, tech giants such as Google, Amazon and Facebook have taken action voluntarily and have to date already removed tens of thousands of ads and posts seeking to profit from people’s fear and spread disinformation. In Finland, online marketplace Tori.fi has banned the sale of face masks and disinfectants as well as advertisements claiming that a product could protect against or prevent coronavirus infections or stop the spread of the virus.

Online marketplaces and tech companies have taken the initiative in championing responsible marketing and ensuring the availability of correct information in this crisis. From a lawyer’s perspective, this active social role taken by various companies is a voluntary and advance filtering by these companies of marketing that could be deemed illegal.

Prohibition of Unfair Marketing and Inappropriate Practices Seeks to Protect Consumers

The Consumer Protection Act states that no conduct that is inappropriate or otherwise unfair from the point of view of consumers shall be allowed in marketing.

Marketing is considered unfair if it is clearly in conflict with social values. The unfairness of marketing is assessed by taking into account all of the circumstances of each individual case, so it is an overall case-by-case assessment. There is no doubt that the current public health emergency would affect this assessment.

Marketing is considered inappropriate if it violates generally accepted business behaviour and the marketing clearly undermines the ability of consumers to make a reasoned purchasing decision or other decision relating to consumer goods. This assessment requires that the marketing would lead to a consumer making a decision that they would not have made without the behaviour. If marketing is targeted at a group that is particularly susceptible to influence, the inappropriateness of the marketing will be assessed from the perspective of this group.

Marketing does not have to have factually led to a consumer buying goods or services and the behaviour does not have to be proven to have caused concrete harm or damage to a consumer for it to be found inappropriate. In this case, a purchasing decision does not just mean whether the consumer purchases goods or services, and includes, e.g. the prices and other conditions under which they buy the commodity.

For example, Amazon has removed over a million products that were misleadingly marketed as preventing coronavirus infection or that had extortionate prices, and Facebook and its subsidiaries announced that they are blocking the advertising of face masks entirely.

Market Products Truthfully

The law prohibits marketing that provides false or misleading information. Specifically, this prohibition means that the key information on a commodity must be true, and information that is true in and of itself cannot be presented in a misleading manner.

So, for example, marketing face masks as protection against the epidemic is clearly misleading, as scientists and medical professionals have been clear that wearing a face mask will not protect a healthy person from infection. By contrast, face masks are recommended for people who have already been infected, as they could prevent them from spreading the infection.

Despite this people have been stockpiling face masks around the globe, and prices have gone through the roof. This has been a cause for concern, for example, in the United States, where face masks have been aggressively marketed to consumers, leading to an explosion in demand. At worst, this could lead to healthcare personnel running out of masks, which would place society at large at risk.

Responsible Marketing and Information Are Key in a Crisis

In a crisis, the marketing, decision making and publication of decisions by companies have a major impact on whether a company ultimately incurs goodwill or badwill.

For example, Google’s CEO Sundar Pichai published a release stating that Google is approaching the situation responsibly, fully aware that many rely on Google’s search engine every day. The company announced that it is combating false information, e.g. by directing searches relating to the coronavirus primarily to the sites of the WHO and national authorities and by removing all advertisements capitalising on the epidemic from Google Ads.

It is a good idea to be particularly careful even if your business does not revolve around face masks. For example, if you are marketing nutritional supplements or other health products, unjustified claims that your product may curb the symptoms of coronavirus or help protect against it would very likely be considered, inter alia, misleading and both unfair and inappropriate behaviour. In the current circumstances, this could also happen if your marketing excessively emphasiseas the disinfectant properties of your cleaning product.

Latest references

We are acting as the lead counsel to Fortum in a cross-border transaction in which Fortum is selling its recycling and waste business. The business is sold to thematic impact investing firm Summa Equity through its portfolio company NG Group. The debt-free purchase price is approximately EUR 800 million. The transaction is subject to authority approval and customary closing conditions. Fortum’s recycling and waste business to be sold comprises municipal and industrial waste management and end-to-end plastics, metals, ash, slag and hazardous waste treatment and recycling services. These businesses are located in Finland, Sweden, Denmark and Norway and currently employ approximately 900 employees.
Case published 18.7.2024
We successfully represented Onses Finland Oy before the Finnish Market Court in an exceptionally extensive dispute concerning alleged trademark infringement and unfair business practice. Our client, Onses Finland Oy, is a Finnish sports drink company and the owner of the sports drink brand ONSE. In the spring of 2023, the Polish beverage company OSHEE Polska Sp. z o.o. filed legal action against our client, alleging that the ONSE trademarks and product packaging infringed the OSHEE trademarks. The plaintiff’s secondary claims concerned alleged slavish imitation of the OSHEE sports drink packaging and exploitation of the reputation of the plaintiff. The plaintiff based its suit on registered trademarks as well as allegedly established and reputed figurative and three-dimensional trademarks. The Market Court rejected all of the plaintiff’s claims. The Market Court held that the marks invoked in the suit were neither established nor marks with a reputation in Finland. As regards the registered trademarks, the Market Court found that there was no likelihood of confusion between the OSHEE and ONSE trademarks. As to the secondary claims, the Market Court held that the sports drink packaging used by the plaintiff was a normal beverage bottle, the design of which was partly determined by functional factors. The Market Court also found that there were several blue sports drinks available on the market and that the plaintiff’s product was not the first blue sports drink on the market. The plaintiff failed to show that its product packaging was original or well-known to the average consumer at the time of the launch of our client’s ONSE sports drink product, and the Market Court thus rejected the claims on slavish imitation and exploitation of reputation. The Market Court ordered the plaintiff to pay all of our client’s legal costs with statutory interest. The judgment (MAO:280/2024) is not final.
Case published 11.6.2024
We acted as the legal and ESG advisor to Mérieux Equity Partners on the acquisition of a majority stake in Labquality through a leveraged buyout by its buyout fund, Mérieux Participations 4. Existing shareholders of Labquality, including Cor Group and the management, will reinvest a portion of their proceeds into the company in connection with the transaction. Headquartered in Helsinki, Finland, Labquality is a Nordic player specialized in EQA, CRO activities and regulatory affairs, with a strong local presence in Central and Eastern Europe. The company provides a comprehensive array of services for the healthcare, medical technology, and pharmaceutical industries. The company, employing over 120 professionals and supported by a network of more than 150 external experts and consultants across its offices in Finland, Germany, and Poland, serves a diverse clientele of over 8,000 customers, including major pharmaceutical companies in over 60 countries. Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. The transaction will enable Labquality to pursue its buy & build strategy in Europe to accelerate its CRO activities while continuing strong and recurring growth in the EQA segment. Labquality will benefit from MxEP’s sector expertise and financial resources to achieve its ambition of becoming a leading European CRO and EQA platform, with fully integrated regulatory consulting capabilities to serve major customers across Europe.
Case published 4.12.2023
We advised Voisin Consulting Life Sciences (VCLS) on the acquisition of MedEngine, a leading medical science agency in the Nordics. MedEngine is a digitally minded, premium service provider for the pharmaceutical industry, built upon extensive academic expertise and years of experience in the industry. Founded in 2014, MedEngine has a strong presence across the Nordic countries with offices in Helsinki (Finland), Copenhagen (Denmark), and Stockholm (Sweden). Founded in 1997, VCLS provides end-to-end HealthTech solutions to support biotechnology, pharmaceutical and MedTech manufacturers throughout their product development. With offices in the US, France, UK, Switzerland, Denmark, Madagascar, India, and China, VCLS serves a broad range of developers and investors in HealthTech.
Case published 7.11.2023